How KPV interacts with melanocortin receptors
A three-amino-acid tail of alpha-MSH that carries the anti-inflammatory message without the pigment-related signal.
TL;DR
- KPV is the last three amino acids of alpha-MSH (in plain English: the small "tail" of a larger natural peptide).
- Animal and cell research links it to lower inflammatory signaling, partly through melanocortin pathways.
- The published mechanism work is preclinical. Human clinical trial data is limited.
What it is
KPV stands for the three amino acids it contains: lysine, proline, and valine. It is the C-terminal tail of alpha-MSH (alpha-melanocyte-stimulating hormone) — a peptide the body makes that helps regulate skin color, appetite, and inflammation. Researchers separated the KPV fragment because that small piece appears to carry the anti-inflammatory message without driving pigment changes (Luger and Brzoska, Annals of the New York Academy of Sciences, 2007).
How it works
Think of alpha-MSH as a long voicemail with two messages: one about skin pigment, one about cooling inflammation. KPV is the short clip of the second message.
Research suggests KPV reduces signaling through NF-kB (in plain English: a switch inside cells that turns inflammation on). Some evidence points to action through melanocortin-1 receptors on the cell surface; other evidence suggests KPV slips into the cell directly to dampen inflammatory transcription (Brzoska et al., Endocrine Reviews, 2008).
The result in animal models has been less swelling and less immune-cell activation. The honest qualifier: most of this evidence is in rodents and cultured cells.
Who asks about it
People usually arrive at KPV after reading about it in a gut-inflammation or skin context. The follow-up is the same one we hear with most peptides: what is it actually doing? That is what this post tries to answer without overselling it.
What the research says
Published animal work has linked KPV to lower inflammation in colitis models, allergic skin models, and joint inflammation models (Brzoska et al., 2008). The pattern across studies is consistent. What the field still lacks is large, well-controlled human trials. The leap from a rodent colon to a human gut is a real leap, and the data to make it is not there yet.
What to know before considering it
FDA removed KPV from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, KPV is not in any FDA 503A category and is not on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding KPV to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision. Any physician conversation about KPV has to start with that regulatory status. Side effects in the published literature are limited because the human research is limited.
The Halftime POV
KPV is one of the more interesting small peptides in the published literature because the mechanism story is unusually clean for animal data. That does not change the fact that the human data is thin and FDA has not made a final decision on its compounding status. We would rather say that plainly than dress up cell-culture results.
Related reading:
- KPV: the alpha-MSH fragment and what it is
- KPV and the published anti-inflammatory research
- Category 1 vs Category 2 peptides: the access framework
FAQ
Q: How does KPV work? A: Animal and cell studies suggest KPV reduces inflammatory signaling by interacting with melanocortin pathways. Some of the effect appears to happen inside the cell rather than at the typical surface receptor. Most evidence is preclinical.
Q: Is KPV the same as alpha-MSH? A: No. KPV is the three-amino-acid tail of the larger alpha-MSH peptide. It carries the anti-inflammatory portion of the parent molecule without the pigment-related effects.
Q: Is KPV FDA-approved? A: No. KPV is not FDA-approved. FDA removed KPV from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, KPV is not in any FDA 503A category and is not on the 503A bulks list.
Disclaimer
FDA removed KPV from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, KPV is not in any FDA 503A category and is not on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding KPV to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides. Endocrine Reviews, 2008.
- Luger TA, Brzoska T. Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Annals of the New York Academy of Sciences, 2007.
Frequently asked questions
How does KPV work?
Animal and cell studies suggest KPV reduces inflammatory signaling by interacting with melanocortin pathways. Some of the effect appears to happen inside the cell rather than at the typical surface receptor. Most evidence is preclinical.
Is KPV the same as alpha-MSH?
No. KPV is the three-amino-acid tail of the larger alpha-MSH peptide. It carries the anti-inflammatory portion of the parent molecule without the pigment-related effects.
Is KPV FDA-approved?
No. KPV is not FDA-approved. FDA removed KPV from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, KPV is not in any FDA 503A category and is not on the 503A bulks list.
Keep reading
Buying peptides online? There is a route with labs first and a licensed physician.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.